

### **ASX ANNOUNCEMENT**

17 October 2017

## **CORPORATE UPDATE**

eSense-Lab Ltd (ASX: ESE) would like to share the enclosed Company presentation and eSense-Lab Product Video that will be used by the Chief Executive Officer and Chairman during the Company's Australian Roadshow this week.

The video can be viewed on the Company's Homepage via the following link: www.esense-lab.com

#### **Ends**

#### About eSense-Lab

eSense-Lab Limited (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense—Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost.

To learn more about eSense – Lab, visit www.esense-lab.com

#### All enquires please contact:

Corporate Advisors
Otsana Capital
108 Outram Street
West Perth WA 6005
Telephone: +61 8 9486 7244
www.otsana.com





# Growth Strategy

#### **COMMITMENT TO IPO STRATEGY**

of revenue growth, cost optimization and scaling efforts, to build a leading B2B enterprise technology company while creating substantial shareholder value via our 3 tiered approach



## **Accelerating sales momentum**

- Signed strategic MOUs
- Immediate potential sales growth
- Continued delivery of contracted quantities and additional product development with Allor
- Expanding footprint in USA
- Penetration into Europe
- Negotiation in new and emerging markets

### Continued investment in product and technology

- New R&D and production facilities
- Improved technological innovations
- Engaging with leaders in the field for potential JV and collaborative opportunities
- Innovative product development for existing and new verticals
- Continual improvement on existing profiles

## Disciplined expense optimization and controls

- Reduced monthly operating expenses via;
  - Increased margins from improved technology
  - Improved third party contracts

## **Product Development and Sales Process**

1 CLIENT IDENTIFICATION

 Company identifies suitable clients, wholesalers and unique JV opportunities CONTRACT & ORDERS

**PRODUCTION & SALES** 

- Company is engaged in contract (Definitive agreement) to determine procurement milestones, payment terms, price and quantities
- First order placed on contract approval and execution

SAMPLES & MOU

- Company sends samples according to client/partner potential market or production line
- Memorandum of Understanding (MOU) is executed on definitive interest received, outlining milestones and joint strategies

Once a contract is executed, the Company commences full production process (per order basis)

- Final product is packed and shipped according to terms of agreements
- Sales are supported with marketing tools and advise provided by the Company (contract specific)

EXAMINATION AND ASSESMENT

 Business development and commercial opportunities are thoroughly assessed between the contracted parties, identifying revenue streams and other income strategies for the benefit of the company 7 RECURRING SALES

 Recurring sales is the most important inflection point in our supplier/clients relationship. Return clients represent product success in the market

**PROTOTYPE & UNIQUE PRODUCTS** 

- Custom-made product development and formulations upon client request
- R&D activity is designed and implemented per client specifications and end-use applications
- End product (prototype sample) is packed and shipped to client for follow-up



## How we are positioned

1

2

3

4

5

6

7

## CLIENT IDENTIFICATION

 Approached more than 200 potential offtake clients and JV opportunities

**SAMPLES & MOU** 

- Shared samples with more then 200 with potential Clients
- Five Signed MOUs to date

## EXAMINATION & ASSESSMENT

Currently in an advanced phase with 3 companies

# PROTOTYPE & UNIQUE PRODUCTS

 Three custom made projects are under evaluation

# CONTRACT & ORDERS

- Signed a purchase order contract with Allor, with contract initiation announced in April 2017
- Negotiation of two additional contracts are in process

## **SALES**

 Allor – Currently receipts of U\$\$85,000 from customized profiles, from U\$\$470,000 contracted for fulfillment by 30 December 2017

## **RECURRING SALES**

 1200 litres per annum anticipated recurring sales based on existing non-binding MOUs, with the associated Definitive Binding Agreements anticipated to be finalised within a 3 – 9 month period



## **Research & Development Timeline**

| R&D Activity  | Start* | Complete* | Total<br>(months) |
|---|--------|-----------|-------------------|
| GC-MS operation and establishment of a full unique in house terpene library   | Oct-17 | Apr-18    | 6                 |
| Evaluating synergistic/additive effect of eSense products in combination with cannabinoids, endocannabinoids and cannabidiol extractions (Inflammatory model) | Nov-17 | May-18    | 6                 |
| Issue a permit to work with cannabis to be able to analyze its phytochemical composition in-house (Terpene and others)  | Nov-17 | July-18   | 8                 |
| Improving eSense products to increase cannabis oriented aroma   | Dec-17 | Aug-18    | 8                 |
| Further refining of terpene profiles of our current products  | Feb-18 | Oct-18    | 8                 |
| Extending formulations by introducing additional cannabis related phytochemicals such as flavonoids, phenols phytosterol and more                             | Oct-18 | Oct-19    | 12                |



\*Indicative timeline subject to change

eSense-Lab versus our competitors

Benefit



## Competitors

| Detection Level                  | >0.001%                                 | >0.1%                    |
|----------------------------------|---|--------------------------|
| Profiling                        | Chemical, Genetics, mRNA and Proteomics | Chemical only            |
| Detection Capabilities           | Polar and non-Polar phytochemicals      | Non-Polar phytochemicals |
| Focus only on Terpenes           | No                                      | Yes                      |
| End Product                      | 30-100 terpenes                         | 3-15 terpenes            |
| Post processing of 'ingredients' | Yes                                     | No                       |
| Medical grade                    | Yes                                     | No                       |
| Pre-Clinical collaborations      | Yes                                     | No                       |
| Clinical collaborations          | Yes                                     | No                       |